8-K Announcements
6Material company update
Feb 27, 2026·SEC
Material company update
Feb 3, 2026·SEC
Material company update
Jan 28, 2026·SEC
Amneal Pharmaceuticals, Inc.(AMRX)Earnings, Financials & Key Ratios
AMRX•NASDAQ
73.7× P/E·Price updated Jun 19, 2026
AboutAmneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.Show more
- Revenue$3.02B+8.0%
- EBITDA-$5M-101.1%
- Net Income$72M+161.6%
- EPS (Diluted)0.22+157.9%
- Gross Margin36.88%+1.0%
- EBITDA Margin-0.17%-101.0%
- Operating Margin-0.17%-101.9%
- Net Margin2.39%+157.1%
- ROE15.66%+101.1%
AMRX Key Insights
Amneal Pharmaceuticals, Inc. (AMRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 8/9
- ✓Momentum leader: RS Rating 85 (top 15%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading near 52-week high
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AMRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AMRX Price & Volume
Amneal Pharmaceuticals, Inc. (AMRX) stock price & volume — 10-year historical chart
Loading chart...
AMRX Growth Metrics
Amneal Pharmaceuticals, Inc. (AMRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years13.3%
5 Years8.66%
3 Years10.92%
TTM8.05%
Profit CAGR
10 Years-8.2%
5 Years-4.57%
3 Years-
TTM161.65%
EPS CAGR
10 Years-13.14%
5 Years-18.45%
3 Years-
TTM158.84%
Return on Capital
10 Years6.97%
5 Years3.72%
3 Years5.66%
Last Year-0.2%
AMRX Recent Earnings
Amneal Pharmaceuticals, Inc. (AMRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 6/12 qtrs (55%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.27+58.8%
$0.17
Rev
$723M+0.4%
$720M
Q2 2026
Apr 22, 2026Metric
Actual
Est
EPS
$0.27+58.8%
$0.17
Rev
$723M+0.4%
$720M
Q1 2026
Feb 27, 2026Metric
Actual
Est
EPS
$0.21+16.7%
$0.18
Rev
$814M+0.9%
$807M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.17+30.8%
$0.13
Rev
$785M-2.7%
$806M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.27vs $0.17+58.8% | $723Mvs $720M+0.4% |
| Q2 2026 | Apr 22, 2026 | $0.27vs $0.17+58.8% | $723Mvs $720M+0.4% |
| Q1 2026 | Feb 27, 2026 | $0.21vs $0.18+16.7% | $814Mvs $807M+0.9% |
| Q4 2025 | Oct 30, 2025 | $0.17vs $0.13+30.8% | $785Mvs $806M-2.7% |
Based on last 12 quarters of dataView full earnings history →
AMRX Peer Comparison
Amneal Pharmaceuticals, Inc. (AMRX) competitors in Complex generics and injectables — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TEVA | 36.66B | 31.48 | 26.23 | 4.31% | 9.02% | 20.69% | 2.20 | |
 VTRS | 17.9B | 15.37 | -5.12 | -2.98% | -2.04% | -1.97% | 1.00 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 1.29B | 31.85 | 26.76 | 27.37% | 6.29% | 30.81% | 2.67 | |
 SLDB | 648.99M | 8.33 | -4.19 | -74.45% | 0.12 | |||
 MCK | 90.23B | 750.63 | 19.56 | 12.36% | 1.18% | |||
 CAH | 52.19B | 221.77 | 34.38 | -1.87% | 0.62% | |||
 CVS | 125.45B | 98.32 | 70.73 | 7.85% | 0.72% | 3.86% | 1.24 |
Compare AMRX vs Peers
Amneal Pharmaceuticals, Inc. (AMRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AMRX Income Statement
Amneal Pharmaceuticals, Inc. (AMRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.03B | 1.66B | 1.63B | 1.99B | 2.09B | 2.21B | 2.39B | 2.79B | 3.02B |
Revenue Growth % | 1.52% | 60.88% | -2.2% | 22.51% | 5.08% | 5.67% | 8.2% | 16.73% | 8.05% |
Cost of Goods Sold | 507.48M | 946.59M | 1.27B | 1.36B | 1.32B | 1.42B | 1.53B | 1.77B | 1.91B |
COGS % of Revenue | 49.1% | 56.92% | 78.3% | 68.46% | 63.27% | 64.22% | 63.91% | 63.48% | 63.12% |
Gross Profit | 526.18M▲ 0% | 716.4M▲ 36.2% | 353M▼ 50.7% | 628.39M▲ 78.0% | 768.97M▲ 22.4% | 791.46M▲ 2.9% | 863.87M▲ 9.1% | 1.02B▲ 18.1% | 1.11B▲ 9.1% |
Gross Margin % | 50.9% | 43.08% | 21.7% | 31.54% | 36.73% | 35.78% | 36.09% | 36.52% | 36.88% |
Gross Profit Growth % | -11.93% | 36.15% | -50.73% | 78.02% | 22.37% | 2.92% | 9.15% | 18.12% | 9.1% |
Operating Expenses | 300.98M | 440.89M | 601.68M | 537.24M | 616.26M | 886.39M | 659.5M | 771.11M | 713M |
OpEx % of Revenue | 29.12% | 26.51% | 37% | 26.96% | 29.43% | 40.07% | 27.55% | 27.6% | 23.62% |
Selling, General & Admin | 109.05M | 230.44M | 289.6M | 326.73M | 365.5M | 399.7M | 429.68M | 476.44M | 526.83M |
SG&A % of Revenue | 10.55% | 13.86% | 17.81% | 16.4% | 17.46% | 18.07% | 17.95% | 17.05% | 17.45% |
Research & Development | 191.94M | 210.45M | 202.29M | 190.59M | 209.56M | 208.66M | 194.75M | 190.71M | 186.18M |
R&D % of Revenue | 18.57% | 12.65% | 12.44% | 9.56% | 10.01% | 9.43% | 8.14% | 6.83% | 6.17% |
Other Operating Expenses | -47K | 2.85M | 109.79M | 19.93M | 41.19M | 278.03M | 35.07M | 103.96M | 0 |
Operating Income | 245.1M▲ 0% | -19.67M▼ 108.0% | -248.68M▼ 1164.1% | 91.16M▲ 136.7% | 152.72M▲ 67.5% | -94.93M▼ 162.2% | 204.37M▲ 315.3% | 249.33M▲ 22.0% | -5.24M▼ 102.1% |
Operating Margin % | 23.71% | -1.18% | -15.29% | 4.57% | 7.29% | -4.29% | 8.54% | 8.92% | -0.17% |
Operating Income Growth % | -13.96% | -108.03% | -1164.08% | 136.66% | 67.53% | -162.16% | 315.29% | 22% | -102.1% |
EBITDA | 291.04M | 117.73M | -41.45M | 326.54M | 386.12M | 145.25M | 433.77M | 485.52M | -5.24M |
EBITDA Margin % | 28.16% | 7.08% | -2.55% | 16.39% | 18.44% | 6.57% | 18.12% | 17.38% | -0.17% |
EBITDA Growth % | -8.45% | -59.55% | -135.21% | 887.85% | 18.25% | -62.38% | 198.65% | 11.93% | -101.08% |
D&A (Non-Cash Add-back) | 45.94M | 137.4M | 207.24M | 235.39M | 233.41M | 240.18M | 229.4M | 236.19M | 0 |
EBIT | 242.38M | -59.15M | -52.04M | 110.22M | 167.69M | 200.03M | 271.38M | 203.58M | 0 |
Net Interest Income | -71.06M | -143.57M | -168.21M | -146M | -136.32M | -158.67M | -210.63M | -258.6M | 0 |
Interest Income | 0 | 0 | 0 | 0 | 0 | 158.38M | 0 | 0 | 0 |
Interest Expense | 71.06M | 143.57M | 168.21M | 146M | 136.32M | 158.38M | 210.63M | 258.6M | -241.09M |
Other Income/Expense | -73.78M | -183.05M | 28.44M | -126.94M | -121.35M | -153.2M | -244.64M | -304.34M | 144.45M |
Pretax Income | 171.32M▲ 0% | -202.72M▼ 218.3% | -220.24M▼ 8.6% | -35.78M▲ 83.8% | 31.37M▲ 187.7% | -248.13M▼ 891.1% | -40.27M▲ 83.8% | -55.01M▼ 36.6% | 139.21M▲ 353.0% |
Pretax Margin % | 16.57% | -12.19% | -13.54% | -1.8% | 1.5% | -11.22% | -1.68% | -1.97% | 4.61% |
Income Tax | 2M | -1.42M | 383.33M | -104.36M | 11.2M | 6.66M | 8.45M | 18.86M | 11.28M |
Effective Tax Rate % | 1.17% | 0.7% | -174.05% | 291.67% | 35.69% | -2.68% | -20.99% | -34.29% | 8.1% |
Net Income | 167.65M▲ 0% | -169.73M▼ 201.2% | -361.92M▼ 113.2% | 91.06M▲ 125.2% | 10.62M▼ 88.3% | -129.99M▼ 1323.5% | -83.99M▲ 35.4% | -116.89M▼ 39.2% | 72.06M▲ 161.6% |
Net Margin % | 16.22% | -10.21% | -22.25% | 4.57% | 0.51% | -5.88% | -3.51% | -4.18% | 2.39% |
Net Income Growth % | -19.16% | -201.24% | -113.24% | 125.16% | -88.33% | -1323.51% | 35.38% | -39.16% | 161.65% |
Net Income (Continuing) | 169.32M | -201.3M | -603.57M | 68.58M | 20.17M | -254.79M | -48.72M | -73.88M | 72.06M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 10.16M | 391.61M | 114.78M | 53.47M | 6.63M | -89.49M | 41.52M | 64.73M | 77.29M |
EPS (Diluted) | 1.46▲ 0% | -1.33▼ 191.1% | -4.57▼ 243.6% | 0.61▲ 113.3% | 0.07▼ 88.5% | -0.86▼ 1328.6% | -0.48▲ 44.2% | -0.38▲ 20.8% | 0.22▲ 157.9% |
EPS Growth % | 32.73% | -191.1% | -243.61% | 113.35% | -88.52% | -1328.57% | 44.19% | 20.83% | 157.89% |
EPS (Basic) | 1.46 | -1.33 | -4.57 | 0.62 | 0.07 | -0.86 | -0.48 | -0.38 | 0.23 |
Diluted Shares Outstanding | 114.86M | 127.25M | 132.11M | 148.91M | 151.82M | 150.94M | 176.14M | 308.98M | 324.81M |
Basic Shares Outstanding | 114.86M | 127.25M | 132.09M | 149.28M | 148.92M | 150.94M | 174.99M | 308.98M | 313.37M |
Dividend Payout Ratio | 223.84% | - | - | - | - | - | - | - | - |
AMRX Balance Sheet
Amneal Pharmaceuticals, Inc. (AMRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 771.93M | 1.29B | 1.21B | 1.55B | 1.52B | 1.41B | 1.38B | 1.59B | 1.91B |
Cash & Short-Term Investments | 74.17M | 213.39M | 152.32M | 343.07M | 247.79M | 27.8M | 93.74M | 112.42M | 282.03M |
Cash Only | 74.17M | 213.39M | 151.2M | 341.38M | 247.79M | 25.98M | 91.54M | 110.55M | 282.03M |
Short-Term Investments | 0 | 0 | 1.12M | 1.7M | 0 | 1.82M | 2.2M | 1.87M | 0 |
Accounts Receivable | 351.37M | 565.32M | 604.39M | 639M | 694.74M | 741.79M | 645.66M | 775.73M | 895.14M |
Days Sales Outstanding | 124.07 | 124.08 | 135.64 | 117.05 | 121.12 | 122.39 | 98.46 | 101.34 | 108.23 |
Inventory | 284.04M | 457.22M | 381.07M | 490.65M | 489.39M | 530.74M | 581.38M | 612.45M | 606.3M |
Days Inventory Outstanding | 204.29 | 176.3 | 109.23 | 131.28 | 134.84 | 136.34 | 138.72 | 126.05 | 116.14 |
Other Current Assets | 35.12M | 52.82M | 33.13M | 40.96M | 41.95M | 64.37M | 7.57M | 40.7M | 127.71M |
Total Non-Current Assets | 569.96M | 3.07B | 2.46B | 2.45B | 2.42B | 2.39B | 2.09B | 1.91B | 1.77B |
Property, Plant & Equipment | 486.76M | 544.15M | 620.6M | 604.71M | 639M | 589.36M | 550.14M | 523.69M | 550.33M |
Fixed Asset Turnover | 2.12x | 3.06x | 2.62x | 3.30x | 3.28x | 3.75x | 4.35x | 5.34x | 5.49x |
Goodwill | 26.44M | 426.23M | 419.5M | 522.81M | 593.02M | 598.85M | 598.63M | 597.44M | 595.47M |
Intangible Assets | 44.6M | 1.65B | 1.38B | 1.3B | 1.17B | 1.1B | 890.42M | 732.38M | 563.5M |
Long-Term Investments | 0 | 0 | 16.37M | 0 | 0 | 85.59M | 37.09M | 35.92M | 0 |
Other Non-Current Assets | 11.26M | 67.59M | 16.45M | 22.34M | 20.61M | 17.63M | 18.43M | 24.21M | 57.8M |
Total Assets | 1.34B▲ 0% | 4.35B▲ 224.4% | 3.67B▼ 15.8% | 4.01B▲ 9.3% | 3.94B▼ 1.7% | 3.8B▼ 3.6% | 3.47B▼ 8.6% | 3.5B▲ 0.8% | 3.68B▲ 5.1% |
Asset Turnover | 0.77x | 0.38x | 0.44x | 0.50x | 0.53x | 0.58x | 0.69x | 0.80x | 0.82x |
Asset Growth % | 10.1% | 224.37% | -15.78% | 9.28% | -1.66% | -3.56% | -8.6% | 0.83% | 5.05% |
Total Current Liabilities | 296.88M | 553.85M | 550.41M | 676.9M | 677.24M | 752.8M | 846.6M | 1.13B | 881.63M |
Accounts Payable | 70.01M | 114.85M | 103.02M | 154.14M | 131.08M | 166.84M | 143.57M | 259.84M | 0 |
Days Payables Outstanding | 50.36 | 44.28 | 29.53 | 41.24 | 36.12 | 42.86 | 34.26 | 53.48 | - |
Short-Term Debt | 89.17M | 21.45M | 21.48M | 45.23M | 30.61M | 89.96M | 213.13M | 324.21M | 21.58M |
Deferred Revenue (Current) | 137.08M | 17.43M | 0 | 0 | 0 | 0 | 398.41M | 0 | 0 |
Other Current Liabilities | 72.2M | 200.83M | 176.32M | 207.31M | 120.1M | 263.11M | 3.91M | 222.36M | 860.06M |
Current Ratio | 2.60x | 2.32x | 2.20x | 2.29x | 2.24x | 1.88x | 1.63x | 1.41x | 2.17x |
Quick Ratio | 1.64x | 1.50x | 1.51x | 1.57x | 1.52x | 1.17x | 0.94x | 0.86x | 1.48x |
Cash Conversion Cycle | 278.01 | 256.1 | 215.34 | 207.09 | 219.84 | 215.87 | 202.92 | 173.91 | - |
Total Non-Current Liabilities | 1.42B | 2.9B | 2.77B | 2.97B | 2.9B | 2.84B | 2.56B | 2.42B | 1.91B |
Long-Term Debt | 1.36B | 2.63B | 2.61B | 2.83B | 2.72B | 2.63B | 2.43B | 2.16B | 102.36M |
Capital Lease Obligations | 39.99M | 39.08M | 123.94M | 115.74M | 111.93M | 108.81M | 95.45M | 91.09M | 0 |
Deferred Tax Liabilities | 2.49M | 1.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10.28M | 231.66M | 35.71M | 31.05M | 65.43M | 97.12M | 41.77M | 163.33M | 1.81B |
Total Liabilities | 1.72B | 3.46B | 3.32B | 3.65B | 3.57B | 3.59B | 3.41B | 3.55B | 2.79B |
Total Debt | 1.48B | 2.69B | 2.77B | 3B | 2.88B | 2.85B | 2.75B | 2.59B | 123.93M |
Net Debt | 1.41B | 2.48B | 2.62B | 2.66B | 2.63B | 2.82B | 2.66B | 2.48B | -158.1M |
Debt / Equity | - | 2.09x | 7.99x | 8.41x | 7.84x | 13.62x | 44.87x | - | 0.13x |
Debt / EBITDA | 5.10x | 22.86x | - | 9.18x | 7.45x | 19.59x | 6.34x | 5.34x | - |
Net Debt / EBITDA | 4.85x | 21.05x | - | 8.14x | 6.81x | 19.41x | 6.13x | 5.11x | - |
Interest Coverage | 3.45x | -0.14x | -1.48x | 0.62x | 1.12x | -0.60x | 0.97x | 0.96x | - |
Total Equity | -375.58M▲ 0% | 1.29B▲ 442.9% | 346.79M▼ 73.1% | 356.74M▲ 2.9% | 366.97M▲ 2.9% | 208.93M▼ 43.1% | 61.3M▼ 70.7% | -44.54M▼ 172.7% | 964.89M▲ 2266.4% |
Equity Growth % | -113.47% | 442.93% | -73.08% | 2.87% | 2.87% | -43.07% | -70.66% | -172.65% | 2266.44% |
Book Value per Share | -3.27 | 10.12 | 2.63 | 2.40 | 2.42 | 1.38 | 0.35 | -0.14 | 2.97 |
Total Shareholders' Equity | -385.74M | 896.36M | 232.01M | 303.27M | 360.34M | 298.42M | 19.78M | -109.27M | 887.6M |
Common Stock | 2.72M | 2.99M | 2.99M | 3M | 3.01M | 3.04M | 3.07M | 3.1M | 0 |
Retained Earnings | -382.79M | -20.92M | -377.88M | -286.82M | -276.2M | -406.18M | -490.18M | -607.06M | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -14.23M | -7.75M | -68K | -41.32M | -24.83M | 9.94M | -32.35M | -65.51M | 0 |
Minority Interest | 10.16M | 391.61M | 114.78M | 53.47M | 6.63M | -89.49M | 41.52M | 64.73M | 77.29M |
AMRX Cash Flow Statement
Amneal Pharmaceuticals, Inc. (AMRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 234.19M | 250.23M | 1.71M | 379M | 241.82M | 65.1M | 345.58M | 295.1M | 339.99M |
Operating CF Margin % | 22.66% | 15.05% | 0.1% | 19.02% | 11.55% | 2.94% | 14.44% | 10.56% | 11.26% |
Operating CF Growth % | 103.53% | 6.85% | -99.32% | 22128.8% | -36.2% | -73.08% | 430.84% | -14.61% | 15.21% |
Net Income | 169.32M | -201.3M | -603.57M | 91.06M | 10.62M | -254.79M | -48.72M | -73.88M | 72.06M |
Depreciation & Amortization | 45.94M | 137.4M | 207.24M | 244.06M | 233.41M | 240.18M | 229.4M | 236.19M | 223.57M |
Stock-Based Compensation | 0 | 167.6M | 21.68M | 20.75M | 0 | 31.85M | 26.82M | 27.77M | 31.95M |
Deferred Taxes | 742K | -9.44M | 371.72M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 14.52M | 148.96M | 124.86M | 84.75M | 131.38M | 107.81M | 185.26M | 109.08M | 12.41M |
Working Capital Changes | -1.05M | 7.01M | -120.22M | -61.63M | -133.59M | -59.95M | -47.19M | -4.07M | 0 |
Change in Receivables | 35.26M | 89.08M | -133.66M | 16.79M | -16.31M | -79.07M | 125.8M | -162.16M | -120.57M |
Change in Inventory | -31.83M | -42.88M | -20.39M | -113.78M | -49.02M | -102.4M | -126.18M | -130.53M | -87.03M |
Change in Payables | 18.11M | -55.21M | -10.26M | 0 | -43.93M | 109.57M | -94.45M | 235.13M | 21.32M |
Cash from Investing | -98.55M | -396.38M | -19.58M | -317.55M | -194.18M | -174.31M | -69.19M | -63M | -112.26M |
Capital Expenditures | -114.27M | -97.09M | -47.18M | -61.84M | -49.43M | -48.8M | -46.8M | -60.34M | -70.06M |
CapEx % of Revenue | 11.06% | 5.84% | 2.9% | 3.1% | 2.36% | 2.21% | 1.96% | 2.16% | 2.32% |
Acquisitions | 15.72M | -324.63M | 34.83M | -251.36M | -141.54M | -84.71M | 0 | 11.99M | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -3.78M | 25.34M | -7.23M | -4.35M | -3.21M | -40.8M | -22.39M | -14.65M | -42.2M |
Cash from Financing | -95.02M | 287.68M | -45.83M | 131.81M | -138.12M | -106.62M | -212.57M | -211.79M | -31.53M |
Debt Issued (Net) | 286.1M | 541.05M | -29.27M | 142.99M | -79.18M | -38.27M | 22.65M | -185.12M | 0 |
Equity Issued (Net) | 0 | 0 | 0 | -863K | 853K | 0 | 0 | 0 | 0 |
Dividends Paid | -375.26M | -183M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -863K | 0 | 0 | 0 | 0 | 0 |
Other Financing | -5.85M | -70.37M | -16.56M | -10.32M | -59.8M | -68.35M | -235.22M | -26.67M | -31.53M |
Net Change in Cash | 40.38M▲ 0% | 140.86M▲ 248.9% | -65.96M▼ 146.8% | 194.3M▲ 394.6% | -90.38M▼ 146.5% | -221.51M▼ 145.1% | 63.88M▲ 128.8% | 19.31M▼ 69.8% | 194.52M▲ 907.2% |
Free Cash Flow | 119.92M▲ 0% | 153.14M▲ 27.7% | -95.73M▼ 162.5% | 317.16M▲ 431.3% | 194.09M▼ 38.8% | -25.5M▼ 113.1% | 276.39M▲ 1184.1% | 220.11M▼ 20.4% | 269.93M▲ 22.6% |
FCF Margin % | 11.6% | 9.21% | -5.89% | 15.92% | 9.27% | -1.15% | 11.55% | 7.88% | 8.94% |
FCF Growth % | 1356.19% | 27.71% | -162.51% | 431.33% | -38.8% | -113.14% | 1184.09% | -20.36% | 22.63% |
FCF per Share | 1.04 | 1.20 | -0.72 | 2.13 | 1.28 | -0.17 | 1.57 | 0.71 | 0.83 |
FCF Conversion (FCF/Net Income) | 1.40x | -1.47x | -0.00x | 4.16x | 22.76x | -0.50x | -4.11x | -2.52x | 4.72x |
Interest Paid | 0 | 131.5M | 158.57M | 130.19M | 0 | 142.72M | 192.81M | 263.52M | 0 |
Taxes Paid | 0 | 34.95M | 10.26M | 0 | 0 | 12.65M | 2.5M | 15.22M | 0 |
AMRX Key Ratios
Amneal Pharmaceuticals, Inc. (AMRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -37.2% | -44.28% | 25.89% | 2.94% | -45.14% | -62.16% | -1394.32% | 15.66% |
Return on Invested Capital (ROIC) | 24.3% | 18.12% | -0.61% | -5.54% | 2.29% | 3.81% | -2.36% | 5.33% | 7.25% | -0.24% |
Gross Margin | 58.68% | 50.9% | 43.08% | 21.7% | 31.54% | 36.73% | 35.78% | 36.09% | 36.52% | 36.88% |
Net Margin | 20.37% | 16.22% | -10.21% | -22.25% | 4.57% | 0.51% | -5.88% | -3.51% | -4.18% | 2.39% |
Debt / Equity | - | - | 2.09x | 7.99x | 8.41x | 7.84x | 13.62x | 44.87x | - | 0.13x |
Interest Coverage | 5.15x | 3.45x | -0.14x | -1.48x | 0.62x | 1.12x | -0.60x | 0.97x | 0.96x | - |
FCF Conversion | 0.55x | 1.40x | -1.47x | -0.00x | 4.16x | 22.76x | -0.50x | -4.11x | -2.52x | 4.72x |
Revenue Growth | 17.54% | 1.52% | 60.88% | -2.2% | 22.51% | 5.08% | 5.67% | 8.2% | 16.73% | 8.05% |
Related:AMRX Dividend History·AMRX Revenue History·AMRX Price History·AMRX P/E History·AMRX Financial Ratios·AMRX Institutional Holders
AMRX SEC Filings & Documents
Amneal Pharmaceuticals, Inc. (AMRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
AMRX Frequently Asked Questions
Amneal Pharmaceuticals, Inc. (AMRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Amneal Pharmaceuticals, Inc. (AMRX) reported $3.02B in revenue for fiscal year 2025. This represents a 248% increase from $866.3M in 2015.
Amneal Pharmaceuticals, Inc. (AMRX) grew revenue by 8.0% over the past year. This is steady growth.
Yes, Amneal Pharmaceuticals, Inc. (AMRX) is profitable, generating $72.1M in net income for fiscal year 2025 (2.4% net margin).
Dividend & Returns
Amneal Pharmaceuticals, Inc. (AMRX) has a return on equity (ROE) of 15.7%. This is reasonable for most industries.
Amneal Pharmaceuticals, Inc. (AMRX) generated $149.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.